The CD47 receptor is an important innate immune checkpoint highjacked by tumors to escape immune surveillance. Unfortunately, the ubiquitous expression of CD47 has made therapeutic targeting with conventional monoclonal antibodies challenging.
Second generation approaches using bispecific antibodies, are emerging in the clinic and will be presented at the upcoming Immunotherapy of Cancer Conference - March 12 to 14th, Munich, Germany.
· Victor Moreno, M.D., PhD (START Madrid-FJD, Spain)
Opportunities and Challenges of CD47 targeted therapy in cancer immunotherapy: Bispecific antibodies targeting CD47
· Julien Montorfani, PhD (Light Chain Bioscience, Switzerland)
The combination of Innate immunity, activating tumor associated macrophages and adaptive immunity, a promising therapeutic approach in heavily treated platinum resistant ovarian cancer patients
We are looking forward to discussing these approaches with the medical and scientific community.
